Rotterdam, The Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a new collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.
Yokohama, Japan: REPROCELL is delighted to announce the launch a new service for consumers, Personal iPS, in which induced pluripotent stem cells (iPSCs) are established for future regenerative medicine treatment.
REPROCELL is pleased to announce that the first patient has been registered and the test article administered at Nagoya University in the Phase II clinical trial of the regenerative medicine product Stemchymal®.
Sign up to receive information from REPROCELL about our products, services, applications, promotions, and news (includes a weekly blog update email).